AR053272A1 - Determinacion de responsivos a la quimioterapia - Google Patents

Determinacion de responsivos a la quimioterapia

Info

Publication number
AR053272A1
AR053272A1 ARP060101849A ARP060101849A AR053272A1 AR 053272 A1 AR053272 A1 AR 053272A1 AR P060101849 A ARP060101849 A AR P060101849A AR P060101849 A ARP060101849 A AR P060101849A AR 053272 A1 AR053272 A1 AR 053272A1
Authority
AR
Argentina
Prior art keywords
phosphorylated
protein
refers
biological sample
cancer cells
Prior art date
Application number
ARP060101849A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR053272A1 publication Critical patent/AR053272A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente se refiere a un método para determinar si una muestra biologica que contiene células cancerígenas de pulmon humanas es sensible a una combinacion de un inhibidor del receptor del factor de crecimiento epidérmico y un agente quimioterapéutico mediante a determinacion de la sobreexpresion de una proteína AKT fosforilada una proteína MAPK fosforilada en la muestra biologica. La presente también se refiere a métodos para obtener un agente candidato o seleccionar una composicion para inhibir la progresion de las células cancerígenas de pulmon en un paciente en el que se utiliza una proteína AKT fosforilada o una proteína MAPK fosforilada.
ARP060101849A 2005-05-11 2006-05-09 Determinacion de responsivos a la quimioterapia AR053272A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010244 2005-05-11
EP05011070 2005-05-23

Publications (1)

Publication Number Publication Date
AR053272A1 true AR053272A1 (es) 2007-04-25

Family

ID=36733489

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101849A AR053272A1 (es) 2005-05-11 2006-05-09 Determinacion de responsivos a la quimioterapia

Country Status (14)

Country Link
US (2) US7655414B2 (es)
EP (1) EP1889066A1 (es)
JP (2) JP4847518B2 (es)
KR (1) KR100962162B1 (es)
CN (1) CN102854315A (es)
AR (1) AR053272A1 (es)
AU (1) AU2006245962B8 (es)
BR (1) BRPI0609096A2 (es)
CA (1) CA2605151A1 (es)
IL (1) IL185631A (es)
MX (1) MX2007013973A (es)
NO (1) NO20074389L (es)
RU (1) RU2416096C2 (es)
WO (1) WO2006119980A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
NZ582618A (en) * 2007-07-13 2012-07-27 Prometheus Lab Inc Drug selection for lung cancer therapy using antibody-based arrays
US20110230506A1 (en) * 2007-08-14 2011-09-22 Paul Delmar Predictive marker for egfr inhibitor treatment
JP2010535517A (ja) * 2007-08-14 2010-11-25 エフ．ホフマン−ラ ロシュ アーゲー Ｅｇｆｒ阻害因子治療のための予測マーカー
BRPI0815545A2 (pt) * 2007-08-14 2015-02-10 Hoffmann La Roche Marcadores preditivos para o tratamento com inibidores de egfr
US8187800B2 (en) 2007-10-15 2012-05-29 Precision Therapeutics, Inc. Methods for selecting active agents for cancer treatment
WO2009089521A2 (en) * 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
DK2250498T3 (da) 2008-02-25 2013-02-04 Nestec Sa Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays
EP2271775A4 (en) * 2008-04-08 2011-09-07 Nuclea Biomarkers Llc BIOMARKERGROUP FOR PREDICTING THE REPRESENTATION OF COLORECTAL CARCINOMA
US20100311084A1 (en) * 2008-05-14 2010-12-09 Precision Therapeutics, Inc. Methods for predicting a patient's response to egfr inhibitors
US20090286276A1 (en) * 2008-05-14 2009-11-19 Brower Stacey L Methods for predicting a patient's response to egfr inhibitors
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
AU2010204741B2 (en) 2009-01-14 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
CA2762983A1 (en) * 2009-05-22 2010-11-25 Sherry X. Yang Akt phosphorylation at ser473 as an indicator for taxane-based chemotherapy
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
CA2862320A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
JP5383836B2 (ja) 2012-02-03 2014-01-08 ファナック株式会社 検索ウィンドウを自動的に調整する機能を備えた画像処理装置
NZ744567A (en) * 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
RU2557976C2 (ru) * 2013-05-07 2015-07-27 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ определения чувствительности клеток рака легкого к цисплатину на основании уровней экспрессии маркерных генов и набор для его осуществления
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2017095632A1 (en) 2015-11-30 2017-06-08 Mayo Foundation For Medical Education And Research Heatr1 as a marker for chemoresistance
AU2017261685B2 (en) * 2016-05-09 2023-09-07 Assistance Publique - Hôpitaux De Paris Methods for classifying patients with a solid cancer
RU2738167C1 (ru) * 2020-06-08 2020-12-09 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии" Министерства здравоохранения Российской Федерации Способ определения эффективности химиотерапии препаратами платины при раке яичников III-IV стадии

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
AU784045B2 (en) * 1999-06-25 2006-01-19 Genentech Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
MXPA03004029A (es) 2000-11-09 2004-02-12 Oncolytics Biotech Inc Metodos para tratamiento de trastornos proliferativos celulares.
ES2305234T3 (es) * 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US7049151B2 (en) * 2001-03-07 2006-05-23 Bio-Rad Laboratories, Inc. Assay system for simultaneous detection and measurement of multiple modified cellular proteins
JP2003189866A (ja) * 2001-12-26 2003-07-08 Sankyo Co Ltd 骨吸収抑制剤探索法
EP1570080A4 (en) 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
CA2512536A1 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US7537906B2 (en) * 2003-01-29 2009-05-26 Nobuhiko Nomura Apoptosis inducer and method of screening for a substance inhibiting acylated homoserine lactone
JP2004229547A (ja) * 2003-01-29 2004-08-19 Nobuhiko Nomura アシル化ホモセリンラクトン阻害物質をスクリーニングする方法
JP2006521793A (ja) 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
JP2004257783A (ja) * 2003-02-25 2004-09-16 Jgs:Kk 金属錯化合物抗癌剤に対する癌細胞の耐性の検査方法及び該耐性を低減させるための薬剤
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia

Also Published As

Publication number Publication date
IL185631A (en) 2011-12-29
US7655414B2 (en) 2010-02-02
AU2006245962B8 (en) 2011-12-08
KR100962162B1 (ko) 2010-06-10
AU2006245962A1 (en) 2006-11-16
WO2006119980A1 (en) 2006-11-16
NO20074389L (no) 2007-12-06
BRPI0609096A2 (pt) 2010-02-17
JP2012021997A (ja) 2012-02-02
JP2008538817A (ja) 2008-11-06
RU2416096C2 (ru) 2011-04-10
JP4847518B2 (ja) 2011-12-28
IL185631A0 (en) 2008-01-06
MX2007013973A (es) 2008-01-11
CN102854315A (zh) 2013-01-02
EP1889066A1 (en) 2008-02-20
KR20070116641A (ko) 2007-12-10
RU2007145514A (ru) 2009-06-20
CA2605151A1 (en) 2006-11-16
US20070054330A1 (en) 2007-03-08
US20100196931A1 (en) 2010-08-05
AU2006245962B2 (en) 2011-11-03

Similar Documents

Publication Publication Date Title
AR053272A1 (es) Determinacion de responsivos a la quimioterapia
UA116618C2 (uk) СКОНСТРУЙОВАНЕ НА ОСНОВІ ЦИСТЕЇНУ АНТИТІЛО ПРОТИ CD79b
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
RS51859B (en) METHOD FOR ANTICIPATING THE RESPONSE TO TREATMENT OF HER DIMENSION INHIBITORS
AR051524A1 (es) Seleccion de pacientes para una terapia con un inhibidor de her
HK1114883A1 (en) Skin aging marker and technique for use thereof
MX2010005081A (es) Metodo para determinar la probabilidad de una respuesta terapeutica en la quimioterapia para el cancer con un glicosido cardiaco.
Miyamoto et al. Single-cell analysis of circulating tumor cells as a window into tumor heterogeneity
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
DE602005024964D1 (de) Verfahren zur beurteilung der malignität einer säuger-krebszelle
DK1761651T3 (da) MNRA-forhold i urinsedimenter og/eller urin som en prognostisk og/eller teranostisk markør for prostatakræft
ES2527776T3 (es) Biomarcadores para predecir la sensibilidad de células a compuestos inmunomoduladores durante el tratamiento del linfoma no Hodgkin
MX2009010620A (es) Marcadores biologicos predictivos de respuesta de artritis reumatoide a antagonistas de celula-b.
WO2014170497A3 (en) Method for identifying the quantitative cellular composition in a biological sample
WO2008021290A9 (en) Organ-specific proteins and methods of their use
TW200716982A (en) Measuring thrombin activity in whole blood
WO2008037700A3 (en) Methods for breast cancer prognosis
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
AR078309A1 (es) Metodo para el diagnostico de esteatohepatitis no alcoholica basado en un perfil metabolomico
Choi et al. Lyso-globotriaosylceramide downregulates KCa3. 1 channel expression to inhibit collagen synthesis in fibroblasts
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE505539T1 (de) Verfahren zur förderung des überlebens und/oder der proliferation einer neuralen stammzelle und zur förderung der neuritenverlängerung, promotor dafür, die neurale stammzelle enthaltende pharmazeutische zusammensetzung, testverfahren und screening-verfahren
BR112012009527A2 (pt) dispositivo para detectar pelo menos um analito.
BR112014003272A2 (pt) método e kit para o sucesso da previsão de fertilização in vitro
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr

Legal Events

Date Code Title Description
FA Abandonment or withdrawal